Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
In our article on agranulocytosis (July 1997) we argued that “routine monitoring...seems sensible for patients beginning treatment with an antithyroid drug” and suggested fortnightly monitoring of the full blood count during the first 3 months of treatment.1 These recommendations have been criticised by several endocrinologists. The substance of their comments is that agranulocytosis induced by antithyroid drugs is extremely rare in Britain, that when it occurs it develops very rapidly and that there is no evidence that monitoring would benefit patients. They also point out that monitoring would complicate and increase the cost of management and would be inconvenient both for patients and their medical carers.
Our recommendations were largely based on the results …